Curtis R. Chong
- Oncology top 2%
- Peptidase Inhibition and Analysis 9
- Cancer Immunotherapy and Biomarkers 6
- Drug Transport and Resistance Mechanisms 4
- Molecular Biology top 5%
- Signaling Pathways in Disease 4
- Biochemical and Molecular Research 3
- Cancer Research top 5%
- Protease and Inhibitor Mechanisms 4
- Cancer Genomics and Diagnostics 3
- Hepatology top 5%
-
- Pneumocystis jirovecii pneumonia detection and treatment 3
Curtis R. Chong
45 papers receiving 4.0k citations
Hit Papers
Peers
Comparison fields: 5 of 144
- Oncology 1.2k
- Computational Theory and Mathematics 446
- Molecular Biology 1.9k
- Cancer Research 377
- Hepatology 199
Countries citing papers authored by Curtis R. Chong
This map shows the geographic impact of Curtis R. Chong's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Curtis R. Chong with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Curtis R. Chong more than expected).
Fields of papers citing papers by Curtis R. Chong
This network shows the impact of papers produced by Curtis R. Chong. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Curtis R. Chong. The network helps show where Curtis R. Chong may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Curtis R. Chong, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2019 | 74 | |
| 2 | 2016 | 67 | |
| 3 | 2016 | 21 | |
| 4 | 2016 | 115 | |
| 5 | 2014 | 69 | |
| 6 | 2012 | 33 | |
| 7 | 2011 | 141 | |
| 8 | 2010 | 421 | |
| 9 | 2010 | 95 | |
| 10 | Abstract #5582: Itraconazole as a novel Hedgehog pathway antagonist in cancer therapy | 2009 | 1 |
| 11 | 2008 | 92 | |
| 12 | In vivo testing of Mycophenolic acid (MPA) in primary pancreatic cancer (PaCa) xenografts | 2007 | 1 |
| 13 | New uses for old drugsbreakdown → | 2007 | 794 |
| 14 | 2007 | 190 | |
| 15 | 2006 | 82 | |
| 16 | 2006 | 221 | |
| 17 | 2004 | 47 | |
| 18 | 2003 | 88 | |
| 19 | 1998 | 78 | |
| 20 | 1988 | 7 |
About Curtis R. Chong
Curtis R. Chong is a scholar working on Oncology, Cancer Research and Pharmacy, having authored 45 papers that have together received 4.1k indexed citations. Recurring topics across this work include Peptidase Inhibition and Analysis (9 papers), Cancer Immunotherapy and Biomarkers (6 papers), Protease and Inhibitor Mechanisms (4 papers), Drug Transport and Resistance Mechanisms (4 papers), Signaling Pathways in Disease (4 papers), Biochemical and Molecular Research (3 papers), Pneumocystis jirovecii pneumonia detection and treatment (3 papers) and Cancer Genomics and Diagnostics (3 papers). The work is most often cited by research in Oncology (1.2k citations), Computational Theory and Mathematics (446 citations) and Molecular Biology (1.9k citations). Curtis R. Chong has collaborated with scholars based in United States, Canada and Japan. Frequent co-authors include David Sullivan, Pasi A. Jänne, Jun O. Liu, Lirong Shi, Shridhar Bhat, Xiaochun Chen, Jing Xu, Carol A. Beuchat, Jun Lu and Joong Sup Shim. Their work appears in journals such as Nature, New England Journal of Medicine and Proceedings of the National Academy of Sciences.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.